Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (66)

I-039Miguel Allo

PHARMACOKINETIC–PHARMACODYNAMIC MODELING AND IN VIVO DRUG RELEASE EVALUATION OF CARVEDILOL CONTROLLED-RELEASE FORMULATIONS IN SPONTANEOUSLY HYPERTENSIVE RATS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-040Pavel Balazki

Automating Scalable End-to-End MIDD Workflows: A Database-Driven Framework for Modular PBPK-QSP Assembly using the Open Systems Pharmacology Suite

Wed, Jun 3, 2026 10:30AM–12:00PM

I-041Yinru Chen

Defining site-relevant PK/PD targets for nemonoxacin dosing in Streptococcus pneumoniae-associated community-acquired pneumonia through a translational PK/PD approach

Wed, Jun 3, 2026 10:30AM–12:00PM

I-042Anthéa Deschamps

Mechanistic biomarker model of serum creatinine in critically ill patients

Wed, Jun 3, 2026 10:30AM–12:00PM

I-043Maud Hennion

Translational Modeling Based on a Semi-Mechanistic Target-Mediated Drug Disposition (TMDD) Approach

Wed, Jun 3, 2026 10:30AM–12:00PM

I-044Hyeseon Jeon

Meta-analytic prior integration reduces prior dependency in sparse TDM-based PopPK modeling: Application to infliximab in pediatric IBD

Wed, Jun 3, 2026 10:30AM–12:00PM

I-045Jeroen Koomen

MODEL-INFORMED APPROACHES FOR PEDIATRIC TYPE 2 DIABETES EVIDENCE GENERATION: INSIGHTS FROM A MODEL-BASED LONGITUDINAL HBA1C META-ANALYSIS FROM EMA MARKETING AUTHORIZATION APPLICATIONS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-046Min Li

Integrated Pharmacokinetics–Receptor Occupancy Modeling of EVER001 to Guide Clinical Efficacious Dose Projection for Primary Membranous Nephropathy

Wed, Jun 3, 2026 10:30AM–12:00PM

I-047Oleg Milberg

MECHANISTIC TARGET-MEDIATED POPULATION PK/PD MODELLING OF REGN7508Cat ACROSS HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY POPULATIONS WITH TRANSLATIONAL EVALUATION IN PATIENTS WITH PICCS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-048Catherine Ollagnier

TRANSLATIONAL MODELING PLATFORM TO CONNECT IN VITRO POTENCY TO
PRECLINICAL WEIGHT LOSS FOR GLP-1 RECEPTOR AGONISTS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-049Zvonimir Petric

From Modeling and Simulation to Personalized Dosing Decisions in IBD: Moving Beyond the Arbitrarily (Pre)Defined Therapeutic Windows and One-Size-Fits-All Dosing Paradigm

Wed, Jun 3, 2026 10:30AM–12:00PM

I-050Stephan Schaller

A Modular PBPK-QSP Platform for Renal–Cardiovascular Pharmacology: Simulating RAAS-Targeted Therapies and Drug-Induced Kidney Injury

Wed, Jun 3, 2026 10:30AM–12:00PM

I-051KILELA Songela Reagan

APPLICATION OF PHARMACOKINETIC MODELING AND SIMULATION IN THE BIOEQUIVALENCE ASSESSMENT OF GENERIC DRUGS: THE CASE OF LUMEFANTRINE

Wed, Jun 3, 2026 10:30AM–12:00PM

I-052Pieter Van Brantegem

Global sensitivity analysis of a mechanistic PK/PD model for T cell engager–mediated peripheral B‑cell depletion

Wed, Jun 3, 2026 10:30AM–12:00PM

I-053Thi Ngoc Anh Vu

Beyond the Michaelis–Menten: A Modified Enzyme Kinetics Framework for Bottom-Up PBPK Modeling and Its Implementation in the Simcyp® Platform

Wed, Jun 3, 2026 10:30AM–12:00PM

I-054Michael Williams

Population K-PD modeling incorporating CFB to mediate suppression of CAP activity informs AZD6912 early clinical development

Wed, Jun 3, 2026 10:30AM–12:00PM

I-055Tatiana Zasedateleva

PBPK/PD MODELING TO ASSESS ANTIBODY-INDUCED IMMUNE CELL DEPLETION AND PD-DEPENDENT CLEARANCE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS

Wed, Jun 3, 2026 10:30AM–12:00PM

II-039Md Almomin

QUANTITATIVE DIFFERENCES IN TRENDS OF INFLAMMATORY BIOMARKERS IN PREGNANT AND POSTPARTUM INDIVIDUALS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-040Noah Brostoff

Enrichment, Response Amplification, Separation, and Inclusion: Quantifying Trial Design Trade-offs in SLE with QSP SimPops™ Modeling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-041Huong Tra Dang

Model-based meta-analysis of CGRP antagonists for migraine: A comprehensive evaluation of efficacy and dose-response modelling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-042Alan Faraj

Population pharmacokinetics of an oral combination of decitabine and tetrahydrouridine in healthy volunteers

Wed, Jun 3, 2026 3:20PM–4:50PM

II-043Ana Homšek

Predicting Mucosal Healing in IBD: The Interplay of Platelet Levels and Infliximab Pharmacokinetics

Wed, Jun 3, 2026 3:20PM–4:50PM

II-044Seongwook Jeong

PHARMACODYNAMIC COMPARISON OF THE ADMS INDEX AND BIS DURING SEVOFLURANE ANESTHESIA: CONCENTRATION–EFFECT MODELING, AGREEMENT, AND DYNAMIC PERFORMANCE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-045Victoria Kulesh

Quantitative Systems Immunology: Unraveling Human CD4+ T-Lymphocyte Kinetics, Tissue Distribution, and Aging Using Mechanistic Modeling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-046Rocio Lledo Garcia

MODEL-INFORMED FIXED DOSING OF ROZANOLIXIZUMAB IN gMG: PK/PD ADVANTAGES AND COMPARISON FROM OTHER FcRn BLOCKERS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-047Giulia Monchietto

Initialising a structured framework to generate virtual patient cohorts in support of drug development in rare and pediatric diseases: Collating and developing methodological modelling and simulation techniques under scenarios of limited knowledge availability

Wed, Jun 3, 2026 3:20PM–4:50PM

II-048Neelima Patnaikuni

QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING OF EFFICACY AND NAUSEA OF GLP-1 RECEPTOR AGONIST (RA) SEMAGLUTIDE AND DUAL GLP-1/GIPRA TIRZEPATIDE IN NON-DIABETIC OBESE PATIENTS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-049Sebastian Polak

Development and application of ML based drug renal clearance predictor

Wed, Jun 3, 2026 3:20PM–4:50PM

II-050Clarisse Schumer

Automated model selection for within-host viral dynamics of SARS-CoV-2 and IAV

Wed, Jun 3, 2026 3:20PM–4:50PM

II-051Flávia Teixeira

Population pharmacokinetic modeling to characterize the exposure of LASSBio-1736 in rats

Wed, Jun 3, 2026 3:20PM–4:50PM

II-052Sven van Dijkman

Design and implementation of a model-optimised paroxetine C-QT study

Wed, Jun 3, 2026 3:20PM–4:50PM

II-053Katarina Vučićević

A Population Pharmacokinetic Framework for Adalimumab TDM in Crohn’s Disease

Wed, Jun 3, 2026 3:20PM–4:50PM

II-054Jessica Wojciechowski

INTEGRATED MIXED EFFECTS ANALYSIS OF PHARMACOKINETICS OF RUXOLITINIB CREAM AND IMPLICATIONS ON ITS SAFETY PROFILE IN ADULT PATIENTS WITH ATOPIC DERMATITIS OR VITILIGO

Wed, Jun 3, 2026 3:20PM–4:50PM

II-055Chiara Zecchin

MODEL-BASED META-ANALYSIS TO INFORM CHRONIC KIDNEY DISEASE DRUG DEVELOPMENT

Wed, Jun 3, 2026 3:20PM–4:50PM

III-039Magnus Åstrand

Opemalirsen antisense oligonucleotide targeting the APOL1 mRNA provide dose-dependent APOL1 reduction in plasma

Thu, Jun 4, 2026 9:50AM–11:20AM

III-040Núria Buil-Bruna

From mechanistic insight to parsimonious models: Modelling IL-18 and aletekitug to inform target engagement

Thu, Jun 4, 2026 9:50AM–11:20AM

III-041Gerbert Coen De Waard

Modelling SARS-CoV-2-specific antibody responses to personalize vaccination strategies as a tool for pandemic preparedness

Thu, Jun 4, 2026 9:50AM–11:20AM

III-042Janice Jia Ni Goh

Developing semi-mechanistic population pharmacokinetic models to assess clinical impact of known and novel pharmacogenomic CYP2D6 variants in a diverse Asian population

Thu, Jun 4, 2026 9:50AM–11:20AM

III-043Itziar Irurzun-Arana

PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) MODELING OF GALNAC-SIRNA GSK4532990 HSD17B13 KNOCKDOWN: INFORMING SKYLINE PHASE 2 PRIMARY ENDPOINTS AND OPTIMAL DOSING IN MASH

Thu, Jun 4, 2026 9:50AM–11:20AM

III-044Christos Kaikousidis

Using DeepNLME to identify promising biomarkers with an application to disease progression modelling of Alzheimer’s disease

Thu, Jun 4, 2026 9:50AM–11:20AM

III-045Mathilde Lacroix

DIALYSATE-GUIDED MODEL-INFORMED PRECISION DOSING OF MEROPENEM DURING CRRT

Thu, Jun 4, 2026 9:50AM–11:20AM

III-046Anna Lundahl

popPKPD modeling of AZD7798-mediated depletion of CCR9+ T cells in healthy volunteers

Thu, Jun 4, 2026 9:50AM–11:20AM

III-047Shota Muraki

A QSP Model to Describe the Time Course of Tolvaptan’s Diuretic Effect in Heart Failure Patients with Fluid Overload

Thu, Jun 4, 2026 9:50AM–11:20AM

III-048Alejandro Perez Pitarch

PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION TO CHARACTERIZE PATIENTS WHO MAY BENEFIT FROM MONTHLY DOSING WITH AFLIBERCEPT 8 MG

Thu, Jun 4, 2026 9:50AM–11:20AM

III-049Sylvie Retout

Pharmacokinetic/Pharmacodynamic and Disease Progression Models to support Sefaxersen Phase 2 read out in Patients with Geographic Atrophy

Thu, Jun 4, 2026 9:50AM–11:20AM

III-050Maja Skataric

INTEGRATED POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE MODELING OF ENLICITIDE IN HYPERCHOLESTEROLEMIA PATIENTS SUPPORTS CLINICAL DOSE RECOMMENDATION ACROSS PATIENT SUBGROUPS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-051Charlotte Thomas

Comparative Quantification of Antibiotic Interactions Using Point Estimates, Response‑Surface Models, and Mechanistic Approaches

Thu, Jun 4, 2026 9:50AM–11:20AM

III-052Sergei Vavilov

Integrin α4β7 pathway in the QSP model of IBD describes vedolizumab efficacy

Thu, Jun 4, 2026 9:50AM–11:20AM

III-053Luong Vuong

OPTIMISING POSACONAZOLE DOSING IN CHILDREN THROUGH POPULATION PHARMACOKINETIC MODELLING AND SIMULATION

Thu, Jun 4, 2026 9:50AM–11:20AM

III-054Heejae Won

POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION ANALYSIS OF LESIGERCEPT, A LONG-ACTING IgETrap-Fc PROTEIN, TO SUPPORT DOSE SELECTION IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA

Thu, Jun 4, 2026 9:50AM–11:20AM

III-055Joe Standing

Mechanistic Modelling of SARS-CoV-2 Viral Dynamics and Antiviral Effects to Link Viral Exposure with Clinical Outcomes

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-038Wouter Ahmed

A Joint Model for Torque Teno Virus, Forced Expiratory Volume, Rejection, Infection and Death Dynamics Over a 6-Year Period After Lung Transplantation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-039Salma Bahnasawy

Population Pharmacokinetic Modelling of AZD1705, a GalNAc-conjugated siRNA targeting ANGPTL3, in Participants with Dyslipidaemia

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-041Jelien Den Hollander

Pharmacokinetic-Pharmacodynamic Modelling of Von Willebrand Factor/Factor VIII Prophylaxis in Von Willebrand Disease

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-042Aanisah Hanuun

A SYNCHRONOUS JOINT POPULATION PHARMACOKINETIC MODEL ANALYSIS FOR THE SIMULTANEOUS ASSESSMENT OF TWO ACTIVE PHARMACEUTICAL INGREDIENTS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-043Aya Ismail

A PRECLINICAL PK/PD MODEL OF PYRONARIDINE IN SCID MICE: A TRANSLATIONAL WORKFLOW FOR PREDICTING ANTIMALARIAL EFFICACY IN HUMANS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-044Jasia King

Use of a population pharmacokinetic model to support dose selection for Phase 2a study with AZD4144 IV treatment in participants with acute kidney injury

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-045Pietro Laddomada

Is regrowth of Mycobacterium tuberculosis always a sign of phenotypical resistance? A model-based approach to interpret drug instability and the implications for potency estimation in time-kill assays.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-046Sophie Marolleau

MECHANISTIC MODELLING OF TARGETED-ANTIBACTERIAL-PLASMIDS TRANSFER VIA BACTERIAL CONJUGATION TO GUIDE DESIGN OF RESISTANCE REVERSAL STRATEGIES

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-047Marina Navas Bachiller

Advancing Antimalarial Therapy Using PBBM: Impact of Physiology and Formulation on Artesunate Absorption

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-048Aglaé Perrin

GENOME WIDE ASSOCIATION STUDY OF MODEL-DERIVED TIME TO VIRAL CLEARANCE IN COVID-19: COMPARISON OF METHODS IN A SIMULATION STUDY AND APPLICATION TO THE DISCOVERY TRIALS.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-049Abrar Samman

Comparing Cystatin-C with Serum Creatinine for Predicting Vancomycin Clearance in Critically ill pediatric Patients: A Population Pharmacokinetic Study

Thu, Jun 4, 2026 13:40PM–15:10PM

IV-051Anastasia Tsyplakova

Modeling Treatment Response to Secukinumab in Psoriasis Using Machine Learning and Time-to-Event Modeling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-052Roberto Visentin

Population PK Modelling of Intranasal Midazolam Incorporating Maturation-Informed Paediatric Scaling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-053Zhigang Wang

Model-based meta-analysis (MBMA) of effect of biologics on FEV1 in severe asthma

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-054Keliang Wu

ETHNIC-SPECIFIC ONTOGENY OF INTESTINAL DRUG TRANSPORTERS AND METABOLIZING ENZYMES IN THE CHINESE POPULATION: ABSOLUTE PROTEOMICS AND TRANSCRIPTOMIC CHARACTERIZATION ACROSS DEVELOPMENT

Thu, Jun 4, 2026 1:40PM–3:10PM